Bank of America’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-35,100
Closed -$1.9M 7421
2025
Q3
$1.9M Buy
35,100
+1,100
+3% +$62.9K ﹤0.01% 4859
2025
Q2
$1.87M Hold
34,000
﹤0.01% 4835
2025
Q1
$2.4M Sell
34,000
-32,600
-49% -$2.19M ﹤0.01% 4519
2024
Q4
$4.38M Buy
66,600
+12,000
+22% +$804K ﹤0.01% 3721
2024
Q3
$3.84M Hold
54,600
﹤0.01% 3983
2024
Q2
$4.5M Sell
54,600
-271,400
-83% -$22.6M ﹤0.01% 3709
2024
Q1
$28.5M Buy
326,000
+292,000
+859% +$26.1M ﹤0.01% 1947
2023
Q4
$3.28M Buy
+34,000
New +$3.01M ﹤0.01% 3921
2023
Q3
Sell
-23,900
Closed -$2.07M 7777
2023
Q2
$2.07M Sell
23,900
-86,900
-78% -$8.18M ﹤0.01% 4204
2023
Q1
$10.8M Buy
110,800
+35,500
+47% +$3.68M ﹤0.01% 2752
2022
Q4
$7.79M Hold
75,300
﹤0.01% 2928
2022
Q3
$6.38M Buy
75,300
+47,500
+171% +$4.23M ﹤0.01% 3079
2022
Q2
$2.3M Buy
+27,800
New +$2.21M ﹤0.01% 4180
2022
Q1
Sell
-1,700
Closed -$150K 8271
2021
Q4
$150K Buy
1,700
+200
+13% +$16.5K ﹤0.01% 6657
2021
Q3
$116K Hold
1,500
﹤0.01% 6639
2021
Q2
$125K Hold
1,500
﹤0.01% 6388
2021
Q1
$113K Sell
1,500
-23,900
-94% -$1.95M ﹤0.01% 6334
2020
Q4
$2.23M Sell
25,400
-28,300
-53% -$2.24M ﹤0.01% 3859
2020
Q3
$4.08M Buy
53,700
+1,000
+2% +$101K ﹤0.01% 3097
2020
Q2
$6.5M Sell
52,700
-40,800
-44% -$4.05M ﹤0.01% 2620
2020
Q1
$7.9M Buy
93,500
+15,500
+20% +$1.34M ﹤0.01% 2256
2019
Q4
$6.59M Buy
78,000
+37,500
+93% +$2.83M ﹤0.01% 2973
2019
Q3
$2.73M Sell
40,500
-92,200
-69% -$7.1M ﹤0.01% 3780
2019
Q2
$11.4M Buy
+132,700
New +$11.4M ﹤0.01% 2408
2019
Q1
Sell
-49,700
Closed -$4.23M 7108
2018
Q4
$4.23M Sell
49,700
-75,900
-60% -$7.22M ﹤0.01% 3174
2018
Q3
$12.2M Buy
125,600
+25,600
+26% +$2.56M ﹤0.01% 2290
2018
Q2
$9.42M Buy
+100,000
New +$8.76M ﹤0.01% 2536
2018
Q1
Sell
-451,100
Closed -$40.2M 7107
2017
Q4
$40.2M Buy
451,100
+440,400
+4,116% +$38.3M 0.01% 1241
2017
Q3
$996K Buy
+10,700
New +$945K ﹤0.01% 4510
2017
Q2
Sell
-19,800
Closed -$1.74M 6938
2017
Q1
$1.74M Sell
19,800
-42,100
-68% -$3.75M ﹤0.01% 3992
2016
Q4
$5.13M Buy
61,900
+29,700
+92% +$2.55M ﹤0.01% 2908
2016
Q3
$2.98M Buy
32,200
+7,200
+29% +$678K ﹤0.01% 3301
2016
Q2
$1.95M Sell
25,000
-84,300
-77% -$7.17M ﹤0.01% 3645
2016
Q1
$9.02M Buy
109,300
+104,300
+2,086% +$8.49M ﹤0.01% 2234
2015
Q4
$524K Sell
5,000
-10,000
-67% -$1.04M ﹤0.01% 4793
2015
Q3
$1.58M Sell
15,000
-31,600
-68% -$4.22M ﹤0.01% 3967
2015
Q2
$6.37M Sell
46,600
-33,000
-41% -$4.09M ﹤0.01% 2345
2015
Q1
$9.92M Buy
79,600
+78,500
+7,136% +$8.32M ﹤0.01% 1880
2014
Q4
$99K Sell
1,100
-1,700
-61% -$141K ﹤0.01% 5890
2014
Q3
$202K Sell
2,800
-1,100
-28% -$72.3K ﹤0.01% 5377
2014
Q2
$243K Sell
3,900
-16,400
-81% -$991K ﹤0.01% 5370
2014
Q1
$1.39M Buy
20,300
+15,400
+314% +$1.13M ﹤0.01% 3579
2013
Q4
$345K Sell
4,900
-24,000
-83% -$1.63M ﹤0.01% 5097
2013
Q3
$2.08M Buy
28,900
+11,100
+62% +$738K ﹤0.01% 3237
2013
Q2
$993K Buy
+17,800
New +$1.11M ﹤0.01% 4048

Other funds holding BMRN

Bank of America's BMRN Position: Q1 2026 in Review

Bank of America increased its BioMarin Pharmaceuticals (BMRN) stake by 8.4% in Q1 2026, buying an estimated $4.22M and bringing the position to 936,951 shares worth $52.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

Bank of America first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $342M in Q1 2023. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Bank of America held 936,951 shares of BioMarin Pharmaceuticals worth $52.9M as of Q1 2026.
  • Bank of America bought 72,439 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.22M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1550 holding.
  • Bank of America first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's BioMarin Pharmaceuticals position peaked at $342M in Q1 2023.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.